[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR051771A1 - Acidos amino carboxilicos sustituidos - Google Patents

Acidos amino carboxilicos sustituidos

Info

Publication number
AR051771A1
AR051771A1 ARP050104854A ARP050104854A AR051771A1 AR 051771 A1 AR051771 A1 AR 051771A1 AR P050104854 A ARP050104854 A AR P050104854A AR P050104854 A ARP050104854 A AR P050104854A AR 051771 A1 AR051771 A1 AR 051771A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
alkoxy
independently
halogen
Prior art date
Application number
ARP050104854A
Other languages
English (en)
Original Assignee
Inst Of Pharmaceutical Discove
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Pharmaceutical Discove filed Critical Inst Of Pharmaceutical Discove
Publication of AR051771A1 publication Critical patent/AR051771A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/56—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos utiles en el tratamiento de desordenes metabolicos relacionados con resistencia a la insulina, resistencia a la leptina o hiperglicemia. Comprenden inhibidores de la Proteína tirosina fosfatasa, en particular Proteína tirosina fosfatasa- 1B (PTP-1B), que son utiles en el tratamiento de diabetes y otras enfermedades mediadas por PTP, tales como cáncer, enfermedades neurodegenerativas y similares. También se describen particularmente composiciones farmacéuticas que comprenden a los compuestos de la presente, métodos parta tratar las condicione anteriores usando tales compuestos, métodos para preparar los compuestos e intermediarios. Reivindicacion 1: Un compuesto que tiene la formula (1) y sus sales farmacéuticamente aceptables, en que: R1 es H, alquil C1-6, fenilalquil C1-6 o arilalquenil C1-6; R6 y R7 son independientemente H, alquil C1-6, aril alquil C1-6, alcanoil C1-6 opcionalmente sustituido con 1 o 2 grupos independientemente seleccionados de amino, mono- o di-alquilamino, -NH aril, -N(alquil C1-6)aril y CO2H, arilalcanoil C1-6, alcoxicarbonil C1-6, arilalcoxicarbonil, heteroarilcarbonil, heteroaril, heterocicloalquilcarbonil, -C(O)NH2, -C(O)NH alquil C1-6, -C(O)N alquil C1-6-alquil C1-6, -C(=NH)NH2, -C(=N-C(O)alcoxi C1-6-NH-C(O)alcoxi C1-6 o -SO2-aril, en que la porciones cíclicas de cada uno de los anteriores están opcionalmente sustituidas con 1, 2, 3 o 4 grupos que son independientemente halogeno, alquil C1-6, alcoxi C1-6, NO2, OH, CO2H, CN, alcanoil C2-6, NH2, NH alquil C1-6, N-alquil C1-6-alquil C1-6, haloalquil o haloalcoxi. R8 es H, alquil C1-6, aril alquil C1-6, arilalcanoil C1-6, en que el grupo aril está opcionalmente sustituido con alquil C1-6, alcoxi C1-4, halogeno, NO2, halo alcoxi C1-6 o haloalcoxi C1-4; R20, R21, R22 y R23 se seleccionan independientemente del grupo que consiste de H, arilalcoxi, arilalquil, halogeno, alquil, OH, alcoxi, NO2, NH2, NH alquil C1-6 alquil C1-6, NH-aril, N alquil C1-4-aril, -NHSO2-aril, - N(alquil C1-6)SO2aril, en que el grupo aril está opcionalmente sustituido con 1, 2, 3 o 4 grupos que son independientemente alquil C1-6, alcoxi C1-6, halogeno, OH, halo alquil C1-4, haloalcoxi C1-4; L2 es un enlace, -O- alquil C1-6, -alquil C1-6-O, - N(R8)C(O)-alquil C1-4, -alquil C1-4-C(O)N(R8)-; L3 es un enlace, -O- alquil C1-4-O-, -O- alquil C1-4, -alquil C1-4-, -alquenil C2-6-, -C(O)-, alquil C1-6-O-, -C(O)NH- o -NHC(O)-; L4 es -alquil C1-6-, -S(O)u alquil C1-4, alquil C1-4-S(O)u-alquil C1-4- , alquenil C2-6-, alquil C1-6-O-alquil C1-6-, -O-alquil C1-6- o alquil C1-6-O-; en que u es 0, 1 o 2; El anillo A es fenil, naftil, isoindolil, indolil, piridil, tiazolil, pirimidil, benzofuranil, benciimidazolil o 1H-indazolil, cada uno de los cuales está opcionalmente sustituido con 1, 2, 3 o 4 grupos que son independientemente, halogeno, alquil C1-4, alcoxi C1-4, haloalquil C1-4, haloalcoxi C1-4, NO2, NH2, NH(alquil C1-6) o N(alquil C1-6) alquil C1-6; Q es -heteroaril-alquil C1-4-aril, - aril-alquil C1-4-heteroaril, heteroaril, heterociclo-alquil o aril, cada uno de los cuales está opcionalmente sustituido con 1, 2, 3, 4 o 5 grupos que son independientemente alcoxicarbonil, alquil C1-6, alcoxi C1-6, halogeno, alcanoil C1-6, haloalquil C1-4, haloalcoxi C1-4, NH2, NH (alquil C1-6), N(alquil C1-6) alquil C1-6, fenil, alcanoil C1-6; Q2 es H o aril, en que el aril está opcionalmente sustituido con 1, 2 o 3 grupos que son independientemente alquil C1-6, alcoxi C1-6 o halogeno; e Y e Y' son, independientemente, un enlace o alquil C1-4-.
ARP050104854A 2004-11-18 2005-11-18 Acidos amino carboxilicos sustituidos AR051771A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62897704P 2004-11-18 2004-11-18

Publications (1)

Publication Number Publication Date
AR051771A1 true AR051771A1 (es) 2007-02-07

Family

ID=36096167

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104854A AR051771A1 (es) 2004-11-18 2005-11-18 Acidos amino carboxilicos sustituidos

Country Status (8)

Country Link
US (1) US7498356B2 (es)
EP (1) EP1814869A2 (es)
JP (1) JP2008520693A (es)
AR (1) AR051771A1 (es)
AU (1) AU2005307735A1 (es)
CA (1) CA2588776A1 (es)
TW (1) TW200630354A (es)
WO (1) WO2006055725A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099171A2 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
AU2005302409A1 (en) * 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery Llc Substituted carboxylic acids
CA2588776A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Substituted amino carboxylic acids
WO2008033931A1 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
WO2008033455A2 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
US8273744B2 (en) * 2008-02-04 2012-09-25 Mercury Therapeutics, Inc. AMPK modulators
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
KR20120041702A (ko) 2009-05-28 2012-05-02 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
AR077688A1 (es) 2009-08-04 2011-09-14 Takeda Pharmaceutical Compuestos heterociclicos, utiles en el tratamiento de cancer
US8771840B2 (en) * 2009-11-13 2014-07-08 Semiconductor Energy Laboratory Co., Ltd. Heterocyclic compound, light-emitting element, light-emitting device, electronic device, and lighting device
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011159781A2 (en) * 2010-06-17 2011-12-22 Senomyx, Inc. Bitter taste modulators
CU24330B1 (es) 2013-02-14 2018-03-13 Novartis Ag Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
KR20150119107A (ko) 2013-02-14 2015-10-23 노파르티스 아게 개선된 생체내 효능을 갖는 nep 억제제로서의 치환된 비스페닐 부탄산 유도체
IL277071B2 (en) 2018-03-08 2024-07-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531083B1 (fr) 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE69528197T2 (de) * 1994-12-14 2003-06-05 Santen Pharmaceutical Co., Ltd Neue 1,3-dialkylharnstoff-derivate
GB9518553D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New urea derivatives processes for the preparation thereof and pharmaceutical composition comprising the same
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6232322B1 (en) * 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6420418B1 (en) 1999-08-16 2002-07-16 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
BRPI0409916A (pt) * 2003-04-30 2006-04-25 Inst For Pharm Discovery Inc ácidos carboxìlicos substituìdos com fenila
WO2004099171A2 (en) * 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
CA2588776A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Substituted amino carboxylic acids

Also Published As

Publication number Publication date
JP2008520693A (ja) 2008-06-19
AU2005307735A1 (en) 2006-05-26
US7498356B2 (en) 2009-03-03
WO2006055725A2 (en) 2006-05-26
US20060122223A1 (en) 2006-06-08
TW200630354A (en) 2006-09-01
EP1814869A2 (en) 2007-08-08
WO2006055725A3 (en) 2006-09-28
CA2588776A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
AR051771A1 (es) Acidos amino carboxilicos sustituidos
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
SE0301373D0 (sv) Novel compounds
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR064349A1 (es) Derivados de dihidropiridina de utilidad como inhibidires de la proteina quinasa, un proceso para su preparacion, aldehidos intermediarios de su sintesis, una composicion farmaceutica que los comprende y su utilizacion en la produccion de medicamentos para el tratamiento de trastornos proliferativos
UY28333A1 (es) Inhibidores de caspasa y sus usos.
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
CY1118836T1 (el) Αντι-ιϊκα φωσφονικα αναλογα
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
DK1471057T3 (da) Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
AR011174A1 (es) Compuestos de pirazina, composiciones farmaceuticas que los contienen, su uso en la peparacion de medicamentos y proceso para prepararlos
AR035763A1 (es) Compuestos derivados de diamidas heterociclicas, metodo para controlar una plaga de invertebrados y composicion que lo comprende
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
AR083525A1 (es) Derivados de acido picolinico sustituidos con heterociclos, metodo para prepararlos, uso de los mismos como herbicidas y composiciones herbicidas que los contienen
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR058329A1 (es) Derivados de pirazolo (4,3-c) piridina sustituidos activos como inhibidores de quinasa, un metodo para su preparacion y composicion farmaceutica
CY1111857T1 (el) Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
AR075160A1 (es) Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
AR071619A1 (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal